Treatment of epileptic encephalopathies.

Abstract:

:Epileptic encephalopathy is defined as a condition where the epileptic activity itself may contribute to the severe neurological and cognitive impairment seen, over and above that which would be expected from the underlying pathology alone. The epilepsy syndromes at high risk of this are a disparate group of conditions characterized by epileptic seizures that are difficult to treat and developmental delay. In this review, we discuss the ongoing debate regarding the significance of inter-ictal discharges and the impact of the seizures themselves on the cognitive delay or regression that is a common feature of these syndromes. The syndromes also differ in many ways and we provide a summary of the key features of the early-onset epileptic encephalopathies including Ohtahara and West syndromes in addition to later childhood-onset syndromes such as Lennox Gastaut and Doose syndromes. An understanding of the various severe epilepsy syndromes is vital to understanding the rationale for treatment. For example, the resolution of hypsarrhythmia in West syndrome is associated with an improvement in cognitive outcome and drives treatment choice, but the same cannot be applied to frequent inter-ictal discharges in Lennox Gastaut syndrome. We discuss the evidence base for treatment where it is available and describe current practice where it is not. For example, in West syndrome there is some evidence for preference of hormonal treatments over vigabatrin, although the choice and duration of hormonal treatment remains unclear. We describe the use of conventional and newer anti-epileptic medications in the various syndromes and discuss which medications should be avoided. Older possibly forgotten treatments such as sulthiame and potassium bromide also have a role in the severe epilepsies of childhood. We discuss hormonal treatment with particular focus on the treatment of West syndrome, continuous spike wave in slow wave sleep (CSWS)/electrical status epilepticus in slow wave sleep (ESES) and Landau Kleffner syndrome. The role of the ketogenic diet has in recent years come to the fore of the management of these severe epilepsies and we describe successful use in myoclonic astatic epilepsy, Lennox Gastaut syndrome and Dravet syndrome. It is important that resective epilepsy surgery is not ignored in the management of these children, particularly those with hemi-pathology who may present with ESES and respond well to hemispheric disconnection. Adjunctive and symptomatic surgical treatments such as vagal nerve stimulation and corpus callosotomy may improve seizure burden. Finally, it is vital that the identification and treatment of developmental, behavioural and psychiatric co-morbidities are not neglected and that a rational, holistic approach is taken to the management of epileptic encephalopathies.

journal_name

CNS Drugs

journal_title

CNS drugs

authors

McTague A,Cross JH

doi

10.1007/s40263-013-0041-6

subject

Has Abstract

pub_date

2013-03-01 00:00:00

pages

175-84

issue

3

eissn

1172-7047

issn

1179-1934

journal_volume

27

pub_type

杂志文章,评审
  • Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study.

    abstract:BACKGROUND:Earlier commencement of clozapine has been related to a better response in treatment-resistant schizophrenia. OBJECTIVES:To identify variables that predict clozapine use after a first episode of schizophrenia (FES). METHODS:Patients with FES and ≤15 days of lifetime antipsychotic treatment were followed up...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-016-0358-z

    authors: Üçok A,Çıkrıkçılı U,Ergül C,Tabak Ö,Salaj A,Karabulut S,Correll CU

    更新日期:2016-10-01 00:00:00

  • HIV-related movement disorders: epidemiology, pathogenesis and management.

    abstract::Clinically relevant movement disorders are identified in 3% of patients with HIV infection seen at tertiary referral centres. In the same setting, prospective follow-up shows that 50% of patients with AIDS develop tremor, parkinsonism or other extrapyramidal features. Hemiballism-hemichorea and tremor are the most com...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200216100-00002

    authors: Cardoso F

    更新日期:2002-01-01 00:00:00

  • Antipsychotic polypharmacy in schizophrenia: benefits and risks.

    abstract::Antipsychotic polypharmacy refers to the co-prescription of more than one antipsychotic drug for an individual patient. Surveys of prescribing in psychiatric services internationally have identified the relatively frequent and consistent use of combined antipsychotics, usually for people with established schizophrenia...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11587810-000000000-00000

    authors: Barnes TR,Paton C

    更新日期:2011-05-01 00:00:00

  • Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful?

    abstract::As in all patient populations, epilepsy is common in pregnant women. Consequently, approximately 1 in 200 pregnancies is exposed to antiepileptic drugs (AEDs). Although exposure to AEDs in utero has been associated with an increased risk of major fetal malformations, most women with epilepsy require medication through...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620100-00001

    authors: Adab N

    更新日期:2006-01-01 00:00:00

  • Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.

    abstract::The link between diabetes mellitus and Alzheimer's disease (AD) has been known for the last few decades. Since insulin and insulin receptors are known to be present in the brain, the downstream signalling as well as the effect of hyperinsulinemia have been extensively studied in both AD and Parkinson's disease. Glucag...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0301-8

    authors: Calsolaro V,Edison P

    更新日期:2015-12-01 00:00:00

  • An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy.

    abstract::Neuropathic pain is a persistent pain condition that develops secondary to nerve injury. The two most common types of peripheral neuropathic pain are post-herpetic neuralgia (PHN) and painful diabetic neuropathy (PDN). Amitriptyline, nortriptyline, desipramine and imipramine are TCAs that have been shown to be effecti...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200822050-00005

    authors: Zin CS,Nissen LM,Smith MT,O'Callaghan JP,Moore BJ

    更新日期:2008-01-01 00:00:00

  • The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review.

    abstract::The issue of antipsychotic treatment during pregnancy is subject to substantial uncertainty and some controversy among healthcare providers, specifically pertaining to second-generation antipsychotics (SGAs) that are subject to a large gap in safety data during pregnancy compared with antidepressants. The amount of sa...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0517-5

    authors: Damkier P,Videbech P

    更新日期:2018-04-01 00:00:00

  • Spotlight on levetiracetam in epilepsy.

    abstract::Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial-onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial-onset seizu...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208340-000000000-00000

    authors: Lyseng-Williamson KA

    更新日期:2011-10-01 00:00:00

  • Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders.

    abstract::Alcoholic patients suffer from harmful allostatic neuroplastic changes in the brain causing an acute withdrawal syndrome upon cessation of drinking followed by a protracted abstinence syndrome and an increased risk of relapse to heavy drinking. Benzodiazepines have long been the treatment of choice for detoxifying pat...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0240-4

    authors: Hammond CJ,Niciu MJ,Drew S,Arias AJ

    更新日期:2015-04-01 00:00:00

  • A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.

    abstract:INTRODUCTION:The gabapentinoids pregabalin and gabapentin are being increasingly prescribed for a range of clinical conditions. Recently, although gabapentinoids at therapeutic dosages may present with low addictive liability levels, cases of misuse and rising numbers of related fatalities have been reported. OBJECTIV...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-016-0359-y

    authors: Chiappini S,Schifano F

    更新日期:2016-07-01 00:00:00

  • Pregabalin: as adjunctive treatment of partial seizures.

    abstract::Pregabalin, the pharmacologically active S-enantiomer of 3-aminomethyl-5-methylhexanoic acid, possesses anticonvulsant activity. Pregabalin binds with high affinity and specificity to voltage-gated calcium channel alpha(2)-delta proteins. The putative mechanism of action of the drug is reduced excitatory neurotransmit...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200519030-00007

    authors: Warner G,Figgitt DP

    更新日期:2005-01-01 00:00:00

  • Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application.

    abstract:BACKGROUND:There are few data about the cost effectiveness of prophylactic medications for migraine. Clinical trials have shown several preventive agents to be useful in reducing the frequency of migraine attack while having tolerable side effects. OBJECTIVE:To compare the cost effectiveness of adding preventive treat...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/11531180-000000000-00000

    authors: Yu J,Smith KJ,Brixner DI

    更新日期:2010-08-01 00:00:00

  • New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential.

    abstract::New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418140-00005

    authors: Connor DF,Steingard RJ

    更新日期:2004-01-01 00:00:00

  • Social anxiety disorder : current treatment recommendations.

    abstract::Social anxiety disorder (SAD) is a prevalent and disabling disorder associated with significant co-morbidity. An increased awareness of SAD over the past two decades has given impetus to advances in the pharmacotherapeutic and psychotherapeutic treatment options for this disorder. On the basis of consistent data from ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200519050-00002

    authors: Muller JE,Koen L,Seedat S,Stein DJ

    更新日期:2005-01-01 00:00:00

  • Affective disorders in patients with HIV infection: impact of antiretroviral therapy.

    abstract::At the beginning of the AIDS pandemic, affective disorders (such as depressed mood) were seen in a considerable number of HIV-1-infected individuals. These disorders were a result of the poor physical condition of the patients, brain involvement by the virus (e.g. encephalopathy) or a reaction to disadvantageous livin...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620060-00005

    authors: Arendt G

    更新日期:2006-01-01 00:00:00

  • Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

    abstract::Alzheimer's disease (AD) is frequently associated with neuropsychiatric symptoms (NPS) such as agitation and aggression, especially in the moderate to severe stages of the illness. The limited efficacy and high-risk profiles of current pharmacotherapies for the management of agitation and aggression in AD have driven ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0270-y

    authors: Liu CS,Chau SA,Ruthirakuhan M,Lanctôt KL,Herrmann N

    更新日期:2015-08-01 00:00:00

  • Remifentanil update: clinical science and utility.

    abstract::The anilidopiperidine opioid remifentanil has pharmacodynamic properties similar to all opioids; however, its pharmacokinetic characteristics are unique. Favourable pharmacokinetic properties, minimally altered by extremes of age or renal or hepatic dysfunction, enable easy titration and rapid dissipation of clinical ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418150-00004

    authors: Beers R,Camporesi E

    更新日期:2004-01-01 00:00:00

  • Treatment Options for Narcolepsy.

    abstract::Narcolepsy type 1 and narcolepsy type 2 are central disorders of hypersomnolence. Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy and is associated with hypocretin-1 deficiency. On the other hand, in narcolepsy type 2, cerebrospinal fluid hypocretin-1 levels are normal and cataplexy ab...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-016-0337-4

    authors: Barateau L,Lopez R,Dauvilliers Y

    更新日期:2016-05-01 00:00:00

  • Seizures in HIV-seropositive individuals: epidemiology and treatment.

    abstract::Seizures are a relatively common occurrence in patients with HIV infection. They may be a result of HIV infection of the CNS or a manifestation of an opportunistic infection. Because seizures are likely to recur in patients infected with HIV and because they are a poor prognostic indicator, it is generally recommended...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200216020-00002

    authors: Romanelli F,Ryan M

    更新日期:2002-01-01 00:00:00

  • Effect of Statin Intensity on the Risk of Epilepsy After Ischaemic Stroke: Real-World Evidence from Population-Based Health Claims.

    abstract:BACKGROUND:Statins possess neuroprotective effects. However, real-world evidence supporting their utility in post-stroke epilepsy (PSE) prevention is limited. OBJECTIVE:The association between statin use, including timing of prescribing (pre-stroke vs post-stroke), type (lipophilicity, intensity of therapy) and dose i...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-018-0501-0

    authors: Lin FJ,Lin HW,Ho YF

    更新日期:2018-04-01 00:00:00

  • Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.

    abstract:BACKGROUND:Although levodopa is considered the most effective pharmacotherapy for motor symptoms of Parkinson's disease (PD), chronic use is associated with motor complications, including fluctuating response and unpredictable, involuntary movements called dyskinesia. ADS-5102 (amantadine) extended-release (ER) capsule...

    journal_title:CNS drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40263-018-0498-4

    authors: Elmer LW,Juncos JL,Singer C,Truong DD,Criswell SR,Parashos S,Felt L,Johnson R,Patni R

    更新日期:2018-04-01 00:00:00

  • Drug Repurposing in Parkinson's Disease.

    abstract::The development of an intervention to slow or halt disease progression remains the greatest unmet therapeutic need in Parkinson's disease. Given the number of failures of various novel interventions in disease-modifying clinical trials in combination with the ever-increasing costs and lengthy processes for drug develo...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0548-y

    authors: Athauda D,Foltynie T

    更新日期:2018-08-01 00:00:00

  • Tianeptine: a review of its use in depressive disorders.

    abstract:UNLABELLED:Tianeptine is an antidepressant agent with a novel neurochemical profile. It increases serotonin (5-hydroxytryptamine; 5-HT) uptake in the brain (in contrast with most antidepressant agents) and reduces stress-induced atrophy of neuronal dendrites. Like the selective serotonin reuptake inhibitors (SSRIs) and...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115030-00006

    authors: Wagstaff AJ,Ormrod D,Spencer CM

    更新日期:2001-01-01 00:00:00

  • Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.

    abstract:BACKGROUND:Walking impairment is a hallmark of multiple sclerosis (MS). It affects > 90% of individuals over time, reducing independence and negatively impacting health-related quality of life, productivity, and daily activities. Walking impairment is consistently reported as one of the most distressing impairments by ...

    journal_title:CNS drugs

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s40263-018-0586-5

    authors: Hobart J,Ziemssen T,Feys P,Linnebank M,Goodman AD,Farrell R,Hupperts R,Blight AR,Englishby V,McNeill M,Chang I,Lima G,Elkins J,ENHANCE study investigators.

    更新日期:2019-01-01 00:00:00

  • Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.

    abstract::Oral fingolimod (Gilenya™), a sphingosine 1-phosphate (S1P) receptor agonist, is the first oral agent and the first in a novel class of disease-modifying therapies (DMTs) to be approved for use in the US for the treatment of relapsing forms of multiple sclerosis (MS). In the EU, fingolimod is approved for use as a sin...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11207350-000000000-00000

    authors: Scott LJ

    更新日期:2011-08-01 00:00:00

  • Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson's Disease.

    abstract::There is escalating interest in cell-based therapies to restore lost dopamine inputs in Parkinson's disease. This is based upon the rationale that implanting dopamine progenitors into the striatum can potentially improve dopamine-responsive motor symptoms. A rich body of data describing clinical trials of previous cel...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00727-3

    authors: Henchcliffe C,Sarva H

    更新日期:2020-06-01 00:00:00

  • Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current Status.

    abstract::Parkinson's disease is a disabling hypokinetic neurological movement disorder in which the aetiology is unknown in the majority of cases. Current pharmacological treatments, though effective at restoring movement, are only symptomatic and do nothing to slow disease progression. Electrophysiological, epidemiological an...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-016-0393-9

    authors: Swart T,Hurley MJ

    更新日期:2016-12-01 00:00:00

  • Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.

    abstract:OBJECTIVE:To assess the relationship between the sustained pain free (SPF) and adverse event (AE) rates associated with six oral serotonin 5-HT(1B/1D) receptor agonists (triptans) used for the treatment of acute migraine, employing data from a previous meta-analysis (that included almotriptan, eletriptan, naratriptan, ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-200721010-00006

    authors: Dodick DW,Sandrini G,Williams P

    更新日期:2007-01-01 00:00:00

  • The new generation of GABA enhancers. Potential in the treatment of epilepsy.

    abstract::gamma-Aminobutyric acid (GABA) is considered to be the major inhibitory neurotransmitter in the brain and loss of GABA inhibition has been clearly implicated in epileptogenesis. GABA interacts with 3 types of receptor: GABAA, GABAB and GABAC. The GABAA receptor has provided an excellent target for the development of d...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115050-00001

    authors: Czuczwar SJ,Patsalos PN

    更新日期:2001-01-01 00:00:00

  • Methylene Blue in the Treatment of Neuropsychiatric Disorders.

    abstract::Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-019-00641-3

    authors: Alda M

    更新日期:2019-08-01 00:00:00